A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding...
Androgenetic AlopeciaMale Pattern Baldness1 moreTo evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the...
Androgenetic AlopeciaMale Pattern Baldness1 moreThe purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the...
Androgenetic AlopeciaMale Pattern Baldness1 moreEvaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
Alopecia Areata Registry
Alopecia AreataAlopecia Totalis3 moreAlopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia areata.
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Alopecia AreataMethodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as significant, was used.
Healthcare Disparities in Alopecia Areata
Alopecia AreataAlopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across people of different ethnicities and deprivation. We aimed to provide the first large-scale, population-based estimate of lifetime risk of AA overall and by important sociodemographic subgroups. As AA is associated with an increased burden of mental health conditions and work-related outcomes (unemployment, time off work), a detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.
Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning...
Hair ThinningThe Viviscal Extra-Strength formulation is an oral food/dietary supplement specifically designed to promote hair growth for women suffering from temporary thinning hair. It does not contain hormones or drugs and has been marketed in Europe for over 15 years. Viviscal Extra-Strength is marketed as Viviscal Maximum Strength in some other territories. The hypothesis of this clinical research study is that the ingestion of Viviscal Extra-Strength over a three (3) month period will strengthen and promote the growth of terminal hairs in female subjects, ages 21-65 years of age with self-perceived thinning hair associated with poor diet, stress, hormonal influences or abnormal menstrual cycles when compared to using the placebo tablet.
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of...
Androgenetic AlopeciaMale Pattern Baldness1 moreEvaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With...
Non-Metastatic Breast CancerThe purpose of this study is to see how many patients develop hair, skin and nail changes due to cancer treatments. The investigators would like to study the clinical factors, genetic markers, and impact on patients' health-related quality of life to learn more about who is at greater risk. We trust that the study will improve our understanding of how cancer patients feel about their skin, hair, and nail conditions. This information will help us determine the burden on breast cancer patients and survivors. It will also help us learn how to prevent these conditions and it may improve the way we treat them and counsel patients.
Design and Validation of a New Assessment Tool for Lichen Planopilaris
Lichen Planopilaris of ScalpLichen Plano-Pilaris2 moreThe study's Primary Objective is to design and validate a grading system for objective and accurate assessment of lichen planopilaris. Secondary Objectives: To assess change in symptoms such as pain and itch using a Numeric Rating Scale(NRS) scores and quality of life using the Dermatology Life Quality Index (DLQI) scores To correlate this grading system with patient skin biopsies evaluating disease activity on a microscopic level To correlate this grading system with digital global photography and trichoscopy